金吾财讯 | 再鼎医药（ZLAB）发布2026财年第二季度财务业绩。财报显示，公司当季实现总营收1.063亿美元，虽同比下降3.4%，但依然超出市场此前预期250万美元。按非美国通用会计准则（Non-GAAP）计算，每股美国存托凭证（ADS）亏损为0.46美元（每股普通股亏损0.05美元），对比上年同期每股ADS亏损0.37美元略有增加，亏损扩大主因系当期许可费支出有所上升。当季营业亏损为7,650万美元，在扣除折旧、摊销及股份支付费用后，调整后营业亏损为6,040万美元。截至2026年6月30日，公司持有的现金、现金等价物、短期投资及受限现金总额达7.175亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.